Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of M136101 for Dry Eye with Obstructive Meibomian Gland Dysfunction
jRCT2031250483Phase 2Active, not recruiting
- Sponsor
- Maruho Co., Ltd.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of selenium sulphide in dry eye syndrome (DED) and meibomian gland dysfunction (MGD) (4 arms), sponsored by Maruho Co., Ltd. Primary endpoint: Tear film break-up time (BUT). Started Dec 2025; status: active, not recruiting.
02
Drugs
selenium sulphide
03
Conditions
dry eye syndrome (DED)meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on jRCT2031250483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250483.